Iovance Biotherapeutics, Inc. (0JDK.L)
0JDK.L Stock Price Chart
Explore Iovance Biotherapeutics, Inc. interactive price chart. Choose custom timeframes to analyze 0JDK.L price movements and trends.
0JDK.L Company Profile
Discover essential business fundamentals and corporate details for Iovance Biotherapeutics, Inc. (0JDK.L) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Pharmaceuticals
IPO Date
29 Jan 2018
Employees
838.00
Website
https://www.iovance.comCEO
Frederick G. Vogt
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
0JDK.L Financial Timeline
Browse a chronological timeline of Iovance Biotherapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 Nov 2025
Upcoming earnings on 6 Aug 2025
Revenue estimate is $66.65M.
Earnings released on 8 May 2025
EPS came in at -$0.36 falling short of the estimated -$0.24 by -48.93%, while revenue for the quarter reached $49.32M, missing expectations by -40.12%.
Earnings released on 27 Feb 2025
EPS came in at -$0.26 surpassing the estimated -$0.27 by +3.75%, while revenue for the quarter reached $73.69M, beating expectations by +2.11%.
Earnings released on 8 Nov 2024
EPS came in at -$0.28 surpassing the estimated -$0.30 by +6.31%, while revenue for the quarter reached $58.56M, missing expectations by -18.19%.
Earnings released on 9 Aug 2024
EPS came in at -$0.34 surpassing the estimated -$0.35 by +3.55%, while revenue for the quarter reached $31.11M, beating expectations by +26.47%.
Earnings released on 10 May 2024
EPS came in at -$0.42 falling short of the estimated -$0.42 by -0.01%, while revenue for the quarter reached $715.00K, missing expectations by -64.76%.
Earnings released on 12 Mar 2024
EPS came in at -$0.45 falling short of the estimated -$0.43 by -5.55%, while revenue for the quarter reached $482.00K, missing expectations by -66.55%.
Earnings released on 8 Nov 2023
EPS came in at -$0.46 falling short of the estimated -$0.45 by -1.80%, while revenue for the quarter reached $469.00K, missing expectations by -89.58%.
Earnings released on 9 Aug 2023
EPS came in at -$0.47 surpassing the estimated -$0.50 by +4.76%, while revenue for the quarter reached $238.00K, missing expectations by -93.91%.
Earnings released on 10 May 2023
EPS came in at -$0.50 surpassing the estimated -$0.57 by +11.38%.
Earnings released on 1 Mar 2023
EPS came in at -$0.64 falling short of the estimated -$0.64 by -0.32%.
Earnings released on 30 Sept 2022
EPS came in at -$0.63 surpassing the estimated -$0.64 by +1.06%.
Earnings released on 30 Jun 2022
EPS came in at -$0.63 falling short of the estimated -$0.61 by -4.17%.
Earnings released on 31 Mar 2022
EPS came in at -$0.58 surpassing the estimated -$0.64 by +8.44%.
Dividend declared on 15 Mar 2022
A dividend of $0.29 per share was announced, adjusted to $0.29.
Earnings released on 25 Feb 2022
EPS came in at -$0.63 falling short of the estimated -$0.56 by -13.42%.
Earnings released on 4 Nov 2021
EPS came in at -$0.53.
Earnings released on 30 Sept 2021
EPS came in at -$0.55.
Earnings released on 31 Mar 2021
EPS came in at -$0.51.
Earnings released on 31 Dec 2020
EPS came in at -$0.47.
Earnings released on 30 Sept 2020
EPS came in at -$0.40.
0JDK.L Stock Performance
Access detailed 0JDK.L performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.